Open-Label Extension for Subjects Who Previously Completed Phase 3 Study ISEE2008.

• Status: Not yet recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: IVERIC bio, Inc.

Criteria

Inclusion Criteria:

• Male or female patients aged 50 years or greater diagnosed with GA inside and/or outside of the fovea who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment.

• Patient must provide new written informed consent for this OLE trial prior to participation.

• Patient must have the ability to return for all trial visits for the duration of the 18-month trial.

Exclusion Criteria:

• Patient did not complete Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham),

• Patient who had the study drug permanently withdrawn for an AE during ISEE2008 are not eligible.

• Patient did not enroll into this OLE trial within the 90 day enrollment period.

• Patient who is pregnant or nursing